Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Yumanity Therapeutics (NASDAQ: YMTX) is set to present at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 p.m. EDT. Richard Peters, M.D., Ph.D., the Company's CEO, will lead the presentation. A live audio webcast will be available on the company's website, with an archived replay accessible afterward. Yumanity focuses on therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's.

BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.

A live audio webcast of the presentation can be accessed through the Events section of the Company's website at yumanity.com/events. An archived replay of the webcast will be available on the Company's website following the live presentation.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006

FAQ

When will Yumanity Therapeutics present at the RBC Capital Markets Global Healthcare Conference?

Yumanity Therapeutics will present on May 19, 2021, at 5:25 p.m. EDT.

Who is presenting for Yumanity Therapeutics at the conference?

Richard Peters, M.D., Ph.D., President and CEO of Yumanity Therapeutics will present at the conference.

How can I watch the Yumanity Therapeutics presentation live?

The presentation can be accessed live through the Events section of Yumanity's website.

What is the focus of Yumanity Therapeutics?

Yumanity Therapeutics focuses on developing therapies for neurodegenerative diseases, including Parkinson's and Alzheimer's.

What is Yumanity's most advanced product candidate?

Yumanity's most advanced product candidate is YTX-7739, currently in Phase 1 clinical development for Parkinson's disease.